Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Alzheimer Disease

ClinicalTrials.gov lists 3,859 trials for Alzheimer Disease or a narrower condition beneath it. Pfizer has the most among industry and government lead sponsors, with 62.

MeSH D000544 Nervous System Diseases C10 F03 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 527 Phase 1/2 Phase 1/2 93 Phase 2 Phase 2 558 Phase 2/3 Phase 2/3 60 Phase 3 Phase 3 286 Phase 4 Phase 4 136 Not applicable Not applicable 1,382 Observational Observational 811 Phase 1 Phase 1 527 Phase 1/2 Phase 1/2 93 Phase 2 Phase 2 558 Phase 2/3 Phase 2/3 60 Phase 3 Phase 3 286 Phase 4 Phase 4 136 Not applicable Not applicable 1,382 Observational Observational 811

Trials per phase (log scale)

1 more section with rows

3,859 of the 3,859 trials are tagged with Alzheimer Disease itself; the rest are tagged with a narrower condition beneath it.

Get the Alzheimer Disease report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Alzheimer Disease trials start? (33)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 9 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 263

1994: 1 trials (Observational 1) 1995: 6 trials (Observational 2, Phase 3 4) 1996: 3 trials (Not applicable 1, Phase 4 1, Phase 2 1) 1997: 3 trials (Observational 1, Phase 3 2) 1998: 4 trials (Phase 4 1, Phase 3 2, Phase 2 1) 1999: 13 trials (Observational 3, Not applicable 1, Phase 4 2, Phase 3 1, Phase 2/3 1, Phase 2 5) 2000: 20 trials (Observational 3, Not applicable 5, Phase 4 1, Phase 3 8, Phase 2 2, Phase 1 1) 2001: 21 trials (Observational 3, Not applicable 4, Phase 4 1, Phase 3 9, Phase 2/3 2, Phase 2 1, Phase 1 1) 2002: 21 trials (Observational 6, Not applicable 2, Phase 4 3, Phase 3 6, Phase 2 4) 2003: 47 trials (Observational 12, Not applicable 3, Phase 4 8, Phase 3 14, Phase 2/3 1, Phase 2 7, Phase 1 2) 2004: 49 trials (Observational 10, Not applicable 5, Phase 4 5, Phase 3 5, Phase 2/3 2, Phase 2 14, Phase 1/2 4, Phase 1 4) 2005: 54 trials (Observational 11, Not applicable 9, Phase 4 7, Phase 3 7, Phase 2 15, Phase 1 5) 2006: 65 trials (Observational 7, Not applicable 6, Phase 4 10, Phase 3 4, Phase 2/3 2, Phase 2 22, Phase 1/2 1, Phase 1 13) 2007: 108 trials (Observational 15, Not applicable 14, Phase 4 9, Phase 3 15, Phase 2/3 3, Phase 2 18, Phase 1/2 1, Phase 1 33) 2008: 115 trials (Observational 15, Not applicable 12, Phase 4 11, Phase 3 14, Phase 2/3 1, Phase 2 26, Phase 1/2 1, Phase 1 35) 2009: 145 trials (Observational 30, Not applicable 17, Phase 4 4, Phase 3 15, Phase 2/3 2, Phase 2 35, Phase 1/2 3, Phase 1 39) 2010: 116 trials (Observational 17, Not applicable 33, Phase 4 5, Phase 3 13, Phase 2/3 2, Phase 2 15, Phase 1/2 3, Phase 1 28) 2011: 102 trials (Observational 25, Not applicable 20, Phase 4 5, Phase 3 5, Phase 2 30, Phase 1 17) 2012: 131 trials (Observational 28, Not applicable 32, Phase 4 8, Phase 3 8, Phase 2/3 5, Phase 2 28, Phase 1/2 3, Phase 1 19) 2013: 115 trials (Observational 23, Not applicable 39, Phase 4 4, Phase 3 12, Phase 2/3 3, Phase 2 10, Phase 1/2 2, Phase 1 22) 2014: 125 trials (Observational 27, Not applicable 39, Phase 4 6, Phase 3 11, Phase 2/3 2, Phase 2 16, Phase 1/2 3, Phase 1 21) 2015: 139 trials (Observational 24, Not applicable 43, Phase 4 4, Phase 3 8, Phase 2/3 5, Phase 2 22, Phase 1/2 4, Phase 1 29) 2016: 180 trials (Observational 44, Not applicable 69, Phase 4 4, Phase 3 11, Phase 2/3 2, Phase 2 20, Phase 1/2 3, Phase 1 27) 2017: 153 trials (Observational 29, Not applicable 60, Phase 4 3, Phase 3 8, Phase 2/3 4, Phase 2 23, Phase 1/2 8, Phase 1 18) 2018: 190 trials (Observational 38, Not applicable 77, Phase 4 3, Phase 3 11, Phase 2/3 3, Phase 2 32, Phase 1/2 3, Phase 1 23) 2019: 226 trials (Observational 47, Not applicable 113, Phase 4 3, Phase 3 6, Phase 2/3 2, Phase 2 23, Phase 1/2 6, Phase 1 26) 2020: 190 trials (Observational 38, Not applicable 85, Phase 4 2, Phase 3 9, Phase 2/3 4, Phase 2 20, Phase 1/2 10, Phase 1 22) 2021: 243 trials (Observational 63, Not applicable 102, Phase 4 2, Phase 3 13, Phase 2/3 2, Phase 2 26, Phase 1/2 8, Phase 1 27) 2022: 263 trials (Observational 71, Not applicable 117, Phase 4 5, Phase 3 13, Phase 2/3 1, Phase 2 28, Phase 1/2 7, Phase 1 21) 2023: 236 trials (Observational 59, Not applicable 115, Phase 4 2, Phase 3 5, Phase 2/3 1, Phase 2 25, Phase 1/2 8, Phase 1 21) 2024: 257 trials (Observational 59, Not applicable 124, Phase 4 4, Phase 3 8, Phase 2/3 4, Phase 2 30, Phase 1/2 4, Phase 1 24) 2025: 258 trials (Observational 52, Not applicable 131, Phase 4 1, Phase 3 17, Phase 2/3 1, Phase 2 31, Phase 1/2 3, Phase 1 22)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 218
2025 258
2024 257
2023 236
2022 263
2021 243
2020 190
2019 226
2018 190
2017 153

Showing 10 of 33 earlier years.

Start your 14-day trial Email me all 33 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 230 trials starting in 2026 and about 240 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 391 trials still running at the 2026-10-09 snapshot; registered median of 25 months across 2,311 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Alzheimer Disease trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 527
Phase 1/2 93
Phase 2 558
Phase 2/3 60
Phase 3 286
Phase 4 136
Not applicable 1,382
Observational 811
Expanded access 6

How many Alzheimer Disease trials are recruiting? (11)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 172
Recruiting 549
Enrolling by invitation 62
Active, not recruiting 148
Available 2

Showing 5 of 11 statuses.

Start your 14-day trial Email me all 11 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Alzheimer Disease trials? (8)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Pfizer 62
Eli Lilly and Company 57
Avid Radiopharmaceuticals 42
National Institute on Aging (NIA) 42
Wyeth is now a wholly owned subsidiary of Pfizer 32

Showing 5 of 8 sponsors.

Start your 14-day trial Email me all 8 sponsors as a PDF

Which drugs are being tested for Alzheimer Disease? (6)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Flortaucipir F18 24
Lecanemab 17
AAB-001 16
Donanemab 15
Florbetaben F18 14

Showing 5 of 6 drugs.

Start your 14-day trial Email me all 6 drugs as a PDF

Interventions as named in the registry (9)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Donepezil HCI (drug) 113
memantine ER 40
F-18 florbetapir 39
Galantamine ER 33
Rivastigmine 5 cm^2 18

Showing 5 of 9 interventions.

Start your 14-day trial Email me all 9 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Alzheimer Disease trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Positive for PDM and had PCC visit 1,775 1
Hospitalizations 1,067 3
Fall 882 132
Positive for PDM and had ER visit 810 1
All other SAEs 732 1

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Alzheimer Disease? (4,196)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Elecsys pTau217 plasma immunoassay detection of amyloid pathology in clinical cohorts. Alzheimer's & dementia : the journal of the Alzheimer's Association 2026 Yes
Long-term thiethylperazine treatment in the Tg4-42 mouse model of Alzheimer's disease mouse: Therapeutic potential vs. adverse effects. Pharmacology, biochemistry, and behavior 2026 Yes
Enhanced quality in primary care for elders with diabetes and dementia: Protocol for a multisite randomized controlled trial. Contemporary clinical trials 2026 Yes
Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial. Nature medicine 2026 Yes
A Randomized Controlled Trial of the Safety and Efficacy of Dronabinol for Agitation in Alzheimer's Disease. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2026 Yes

Showing 5 of 4,196 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.

Browse all condition evidence pages